A prospective study of serum amyloid A in relation to plasma administration in neonatal foals.

Res Vet Sci

Equine Sports Medicine and Surgery, Weatherford, TX, USA. Electronic address:

Published: December 2022

SAA is a commonly used biomarker for measuring acute inflammation in equine practice, and the administration of prophylactic plasma to foals is a routine practice in large breeding farms. Despite this, limited information is available on the values of SAA in healthy or sick neonatal foals following this common procedure. A prospective study was conducted with 31 foals from a veterinary hospital in Texas in one year. Enrolled foals were part of a foaling program, where a prophylactic hyperimmunized plasma was administered 12 h after birth. Blood was collected for SAA measurements at birth and at 12 h (pre-plasma), 13 h (post-plasma), 24 h, 48 h, 72 h, and 96 h. Eight of the foals were clinically ill prior to plasma administration, and 23 foals were clinically normal. The mean SAA of all foals at birth was 1 μg/mL, increased to 11 μg/mL at 12 h (pre-plasma), and at 13 h (post-plasma) was 155 μg/mL. At 13 h, 65% of normal foals and 63% of sick foals had an SAA value >100 μg/mL. Transient but substantial increases in SAA following prophylactic plasma administration were frequently observed in this study. Veterinarians evaluating neonatal foals for clinical disease in the field should be cognizant of the timing of blood sampling in relation to plasma administration.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rvsc.2022.06.028DOI Listing

Publication Analysis

Top Keywords

plasma administration
16
neonatal foals
12
foals
11
prospective study
8
relation plasma
8
foals saa
8
prophylactic plasma
8
12 h pre-plasma
8
pre-plasma 13 h
8
13 h post-plasma
8

Similar Publications

Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling.

Clin Pharmacokinet

January 2025

Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, 4 Rue Gabrielle Perret-Gentil, 1205, Geneva, Switzerland.

Background And Objective: Fexofenadine is commonly used as a probe substrate to assess P-glycoprotein (Pgp) activity. While its use in healthy volunteers is well documented, data in older adult and polymorbid patients are lacking. Age- and disease-related physiological changes are expected to affect the pharmacokinetics of fexofenadine.

View Article and Find Full Text PDF

Background: The mechanism underlying chronic drug-induced liver injury (DILI) remains unclear. Immune activation is a common feature of DILI progression and is closely associated with metabolism. We explored the immunometabolic profile of chronic DILI and the potential mechanism of chronic DILI progression.

View Article and Find Full Text PDF

NIM-1324 is an oral investigational new drug for autoimmune disease that targets the Lanthionine Synthetase C-like 2 (LANCL2) pathway. Through activation of LANCL2, NIM-1324 modulates CD4+ T cells to bias signaling and cellular metabolism toward increased immunoregulatory function while providing similar support to phagocytes. In primary human immune cells, NIM-1324 reduces type I interferon and inflammatory cytokine (IL-6, IL-8) production.

View Article and Find Full Text PDF

Hepatic impairment (HI) trials are traditionally part of the clinical pharmacology development to assess the need for dose adaptation in people with impaired metabolic capacity due to their diseased liver. This review aimed at looking into the data from dedicated HI studies, cluster these data into various categories and connect the effect by HI with reported pharmacokinetics (PK) properties in order to identify patterns that may allow waiver, extrapolations, or adapted HI study designs. Based on a ratio ≥ 2 or ≤ 0.

View Article and Find Full Text PDF

Studies have demonstrated that resveratrol exerts several pharmacological effects. However, the pharmacokinetic parameters are not completely established. This study describes the plasma pharmacokinetics and tissue distribution of resveratrol after administration by different routes and doses in rats.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!